Human PC blocking peptide

This study presents the actual monitoring data and performance analysis results obtained from the 11.15-MW grid-connected Shagaya Photovoltaic Park, Kuwait (latitude 29.2 degrees N, longitude 47.04 degrees W). The plant was specifically built to compare two PV technologies: a Thin-Film (TF) installation of 5.5 MW and a Polycrystalline (PC) silicon installation of 5.6 MW. The plant has been designed as a pilot testbed to evaluate the performance of different grid-tied PV technologies under a hot desert environment. A 25-month monitoring period has provided important information that will be used to prepare the design of upcoming GW-size PV projects at Shagaya. Performance parameters of the PV system evaluated here include: final yield, reference yield, array yield, system losses, array capture losses, cell temperature losses, PV module efficiency, system efficiency, inverter efficiency, performance ratio, and capacity factor. Comparison between the TF and PC PV subsystems reveals no significant difference between the two technologies regarding annual reference yields (1805 kWh/kW for TF and 1810 kWh/kW for PC), performance ratios (80.0% for TF and 80.2% for PC), or system losses (20.04% for TF and 19.81% for PC). The PC panels are affected by slightly higher module capture losses due to their higher negative temperature coefficient. It is found, most importantly, that the two PV subsystems have very similar performance behavior when they have similar capacity and operate under the same Shagaya desert environment with the same stringent operational and maintenance strategies. One disadvantage of the TF subsystem, however, is that it requires 18.5% more land area than the PC subsystem to match the installed capacity. The soiling of panels is substantial and requires monthly cleaning with water, which is scarce in a desert environment. A smaller total panel area for a similar power output could constitute a significant economic advantage for the PC technology under such conditions.

The overexpression of survivin is usually accompanied by an increased resistance of cancer cells to chemotherapeutic agents in addition to cancer aggressiveness. Consequently, survivin is considered as an attractive target to develop new promising anticancer candidates. A series of novel 3-cyanopyridine derivatives was synthesized and assessed for their cytotoxic activity against three human cancer cell lines: prostate carcinoma (PC-3), breast cancer (MDA-MB-231) and hepatocellular carcinoma (HepG2). In addition, their activities were evaluated in comparison with a standard anticancer drug 5-FU. Compounds 5c and 5e both exhibited promising cytotoxicity against all the tested cell lines; especially, 5e showed better cytotoxic effect than the reference drug 5-FU. In order to evaluate the safety of these compounds, they were tested on the normal cell line WI-38, revealing their toxic selectivity toward cancer cells over normal ones. Further studies were performed in order to understand their mechanism of action; we examined the ability of our promising compounds 5c and 5e to induce cell cycle arrest. Both resulted in a notable induction of cell cycle arrest at the G2/M phase, along with an increase in the DNA content in the pre-G1 phase, giving us an indication of the incidence of apoptosis. 5c and 5e were further subjected to additional study using Annexin V-FITC assay in order to evaluate their ability to induce apoptosis. The results showed a marked increase in the early and late apoptotic cells, as well as an increase in the percentage of necrosis. Furthermore, Western blotting assay was accomplished using different concentrations of 5c and 5e. The results revealed a striking reduction in survivin expression through proteasome-dependent survivin degradation in addition to a decrease in the expression of some other inhibitor of apoptosis proteins (IAP) family proteins: Livin, XIAP, and C-IAP1 in a concentration-dependent manner. A docking study of 5c and 5e compounds in the dimerization site of survivin was also performed, showing agreement with the in vitro anti-survivin activity.